Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation

Publisher： Karger

E-ISSN： 1421-9662|132|2|226-232

ISSN： 0001-5792

Source： Acta Haematologica, Vol.132, Iss.2, 2014-04, pp. : 226-232

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib‐thalidomide‐dexamethasone versus bortezomib‐cyclophosphamide‐dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 605-606

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-10 ,pp. : 35-39

Karger

Access to resources Recommend Favorite

Bortezomib, thalidomide and dexamethasone versus bortezomib, cyclophosphamide and dexamethasone as induction therapy prior to ASCT in multiple myeloma – response to Moreau et al

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 604-605

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cyclophosphamide‐based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma

By  

JOURNAL OF CLINICAL APHERESIS, Vol. 30, Iss. 3, 2015-06 ,pp. : 176-182

John Wiley & Sons Inc

Access to resources Recommend Favorite

The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 2, 2015-02 ,pp. : 109-114

John Wiley & Sons Inc

Access to resources Recommend Favorite